{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T02:07:30Z","timestamp":1791338850317,"version":"4.3.1"},"reference-count":93,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2019,11,29]],"date-time":"2019-11-29T00:00:00Z","timestamp":1574985600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"DOI":"10.3389\/fimmu.2019.02668","type":"journal-article","created":{"date-parts":[[2019,11,29]],"date-time":"2019-11-29T11:00:26Z","timestamp":1575025226000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":130,"title":["Mechanisms of Graft-versus-Host Disease Prevention by Post-transplantation Cyclophosphamide: An Evolving Understanding"],"prefix":"10.3389","volume":"10","author":[{"given":"Natalia S.","family":"Nunes","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christopher G.","family":"Kanakry","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2019,11,29]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"339","DOI":"10.1056\/NEJMsa1311707","article-title":"HLA match likelihoods for hematopoietic stem-cell grafts in the U.S. registry","volume":"371","author":"Gragert","year":"2014","journal-title":"N Engl J Med."},{"key":"B2","doi-asserted-by":"publisher","first-page":"197","DOI":"10.1056\/NEJM198901263200401","article-title":"Effect of HLA compatibility on engraftment of bone marrow transplants in patients with leukemia or lymphoma","volume":"320","author":"Anasetti","year":"1989","journal-title":"N Engl J Med."},{"key":"B3","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1016\/0198-8859(90)90071-V","article-title":"Effect of HLA incompatibility on graft-versus-host disease, relapse, and survival after marrow transplantation for patients with leukemia or lymphoma","volume":"29","author":"Anasetti","year":"1990","journal-title":"Hum Immunol."},{"key":"B4","doi-asserted-by":"publisher","first-page":"2473","DOI":"10.1172\/JCI90595","article-title":"Alloimmune T cells in transplantation","volume":"127","author":"DeWolf","year":"2017","journal-title":"J Clin Invest."},{"key":"B5","doi-asserted-by":"publisher","first-page":"232","DOI":"10.1053\/j.seminhematol.2015.03.005","article-title":"Alternative donor allogeneic hematopoietic cell transplantation for acute myeloid leukemia","volume":"52","author":"Kanakry","year":"2015","journal-title":"Semin Hematol."},{"key":"B6","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1038\/nrclinonc.2015.128","article-title":"Modern approaches to HLA-haploidentical blood or marrow transplantation","volume":"13","author":"Kanakry","year":"2016","journal-title":"Nat Rev Clin Oncol."},{"key":"B7","doi-asserted-by":"publisher","first-page":"641","DOI":"10.1016\/j.bbmt.2008.03.005","article-title":"HLA-haploidentical bone marrow transplantation for hematologic malignancies using non-myeloablative conditioning and high-dose, posttransplantation cyclophosphamide","volume":"14","author":"Luznik","year":"2008","journal-title":"Biol Blood Marrow Transplant."},{"key":"B8","doi-asserted-by":"publisher","first-page":"377","DOI":"10.1053\/bbmt.2002.v8.pm12171484","article-title":"Non-myeloablative bone marrow transplantation from partially HLA-mismatched related donors using posttransplantation cyclophosphamide","volume":"8","author":"O'Donnell","year":"2002","journal-title":"Biol Blood Marrow Transplant."},{"key":"B9","doi-asserted-by":"publisher","first-page":"288","DOI":"10.1182\/bloodadvances.2016002766","article-title":"Prospective study of nonmyeloablative, HLA-mismatched unrelated BMT with high-dose posttransplantation cyclophosphamide","volume":"1","author":"Kasamon","year":"2017","journal-title":"Blood Adv."},{"key":"B10","doi-asserted-by":"publisher","first-page":"938","DOI":"10.1182\/blood-2015-09-671834","article-title":"Reduced-intensity transplantation for lymphomas using haploidentical related donors vs HLA-matched unrelated donors","volume":"127","author":"Kanate","year":"2016","journal-title":"Blood."},{"key":"B11","doi-asserted-by":"publisher","first-page":"3141","DOI":"10.1200\/JCO.2015.66.3476","article-title":"Reduced-intensity transplantation for lymphomas using haploidentical related donors versus HLA-matched sibling donors: a center for international blood and marrow transplant research analysis","volume":"34","author":"Ghosh","year":"2016","journal-title":"J Clin Oncol."},{"key":"B12","doi-asserted-by":"publisher","first-page":"360","DOI":"10.1182\/bloodadvances.2018027748","article-title":"PTCy-based haploidentical vs matched related or unrelated donor reduced-intensity conditioning transplant for DLBCL","volume":"3","author":"Dreger","year":"2019","journal-title":"Blood Adv."},{"key":"B13","doi-asserted-by":"publisher","first-page":"1033","DOI":"10.1182\/blood-2015-04-639831","article-title":"Haploidentical transplant with posttransplant cyclophosphamide vs. matched unrelated donor transplant for acute myeloid leukemia","volume":"126","author":"Ciurea","year":"2015","journal-title":"Blood."},{"key":"B14","doi-asserted-by":"publisher","first-page":"3224","DOI":"10.1182\/blood-2009-11-251595","article-title":"High-dose cyclophosphamide as single-agent, short-course prophylaxis of graft-versus-host disease","volume":"115","author":"Luznik","year":"2010","journal-title":"Blood."},{"key":"B15","doi-asserted-by":"publisher","first-page":"3497","DOI":"10.1200\/JCO.2013.54.0625","article-title":"Multi-institutional study of post-transplantation cyclophosphamide as single-agent graft-versus-host disease prophylaxis after allogeneic bone marrow transplantation using myeloablative busulfan and fludarabine conditioning","volume":"32","author":"Kanakry","year":"2014","journal-title":"J Clin Oncol."},{"key":"B16","doi-asserted-by":"publisher","first-page":"3817","DOI":"10.1182\/blood-2014-07-587477","article-title":"Single-agent GVHD prophylaxis with posttransplantation cyclophosphamide after myeloablative, HLA-matched BMT for AML, ALL, and MDS","volume":"124","author":"Kanakry","year":"2014","journal-title":"Blood."},{"key":"B17","doi-asserted-by":"publisher","first-page":"1389","DOI":"10.1182\/blood-2016-09-737825","article-title":"Low immunosuppressive burden after HLA-matched related or unrelated BMT using posttransplantation cyclophosphamide","volume":"129","author":"Kanakry","year":"2017","journal-title":"Blood."},{"key":"B18","doi-asserted-by":"publisher","first-page":"e132","DOI":"10.1016\/S2352-3026(18)30221-7","article-title":"Three prophylaxis regimens (tacrolimus, mycophenolate mofetil, and cyclophosphamide; tacrolimus, methotrexate, and bortezomib; or tacrolimus, methotrexate, and maraviroc) versus tacrolimus and methotrexate for prevention of graft-versus-host disease with haemopoietic cell transplantation with reduced-intensity conditioning: a randomised phase 2 trial with a non-randomised contemporaneous control group (BMT CTN 1203)","volume":"6","author":"Bolanos-Meade","year":"2019","journal-title":"Lancet Haematol."},{"key":"B19","doi-asserted-by":"publisher","first-page":"129","DOI":"10.1016\/S0171-2985(96)80033-7","article-title":"Cyclophosphamide-induced immunological tolerance: an overview","volume":"195","author":"Mayumi","year":"1996","journal-title":"Immunobiology."},{"key":"B20","doi-asserted-by":"publisher","first-page":"683","DOI":"10.1053\/j.seminoncol.2012.09.005","article-title":"Post-transplantation cyclophosphamide for tolerance induction in HLA-haploidentical bone marrow transplantation","volume":"39","author":"Luznik","year":"2012","journal-title":"Semin Oncol."},{"key":"B21","doi-asserted-by":"publisher","first-page":"211ra157","DOI":"10.1126\/scitranslmed.3006960","article-title":"Aldehyde dehydrogenase expression drives human regulatory T cell resistance to posttransplantation cyclophosphamide","volume":"5","author":"Kanakry","year":"2013","journal-title":"Sci Transl Med."},{"key":"B22","doi-asserted-by":"publisher","first-page":"2131","DOI":"10.1182\/blood-2013-10-525873","article-title":"Donor CD4+ Foxp3+ regulatory T cells are necessary for posttransplantation cyclophosphamide-mediated protection against GVHD in mice","volume":"124","author":"Ganguly","year":"2014","journal-title":"Blood."},{"key":"B23","doi-asserted-by":"publisher","first-page":"2357","DOI":"10.1172\/JCI124218","article-title":"Post-transplantation cyclophosphamide prevents graft-versus-host disease by inducing alloreactive T cell dysfunction and suppression","volume":"126","author":"Wachsmuth","year":"2019","journal-title":"J Clin Invest."},{"key":"B24","doi-asserted-by":"publisher","first-page":"e974393","DOI":"10.4161\/2162402X.2014.974393","article-title":"Situational aldehyde dehydrogenase expression by regulatory T cells may explain the contextual duality of cyclophosphamide as both a pro-inflammatory and tolerogenic agent","volume":"4","author":"Kanakry","year":"2015","journal-title":"Oncoimmunology."},{"key":"B25","doi-asserted-by":"publisher","first-page":"84","DOI":"10.1038\/200084a0","article-title":"Prolongation of homograft survival in mice with single doses of cyclophosphamide","volume":"200","author":"Berenbaum","year":"1963","journal-title":"Nature."},{"key":"B26","doi-asserted-by":"publisher","first-page":"297","DOI":"10.1001\/jama.191.4.297","article-title":"Influence of cyclophosphamide on homograft rejection","volume":"191","author":"Brody","year":"1965","journal-title":"JAMA."},{"key":"B27","doi-asserted-by":"publisher","first-page":"909","DOI":"10.1159\/000161757","article-title":"The immune response to heterologous red cells in mice. 3. Cyclophosphamide-induced tolerance to multispecies rd cells","volume":"30","author":"Dietrich","year":"1967","journal-title":"Pathol Microbiol."},{"key":"B28","doi-asserted-by":"publisher","first-page":"833","DOI":"10.1084\/jem.125.5.833","article-title":"Studies on cyclophosphamide-induced tolerance to sheep erythrocytes","volume":"125","author":"Aisenberg","year":"1967","journal-title":"J Exp Med."},{"key":"B29","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1084\/jem.128.1.35","article-title":"The thymus and recovery from cyclophosphamide-induced tolerance to sheep erythrocytes","volume":"128","author":"Aisenberg","year":"1968","journal-title":"J Exp Med."},{"key":"B30","doi-asserted-by":"publisher","first-page":"498","DOI":"10.1038\/213498a0","article-title":"Immunological tolerance induced by cyclophosphamide assayed by plaque spleen cell method","volume":"213","author":"Aisenberg","year":"1967","journal-title":"Nature."},{"key":"B31","first-page":"287","article-title":"Cyclophosphamide-induced immunologic tolerance to skin homografts","volume":"22","author":"Nirmul","year":"1971","journal-title":"Surg Forum."},{"key":"B32","first-page":"403","article-title":"Cyclophosphamide-induced graft-versus-host immunotolerance","volume":"10","author":"Van Winkle","year":"1971","journal-title":"J Reticuloendothel Soc."},{"key":"B33","doi-asserted-by":"publisher","first-page":"378","DOI":"10.1097\/00007890-197104000-00004","article-title":"The effect of cytotoxic drugs on graft-versus-host disease in mice","volume":"11","author":"Owens","year":"1971","journal-title":"Transplantation."},{"key":"B34","first-page":"675","article-title":"Mechanisms and kinetics of cyclophosphamide-induced specific tolerance to skin allografts in mice","volume":"5","author":"Nirmul","year":"1973","journal-title":"Transplant Proc."},{"key":"B35","doi-asserted-by":"publisher","first-page":"139","DOI":"10.1038\/210139a0","article-title":"Production of graft-versus-host disease in the rat and its treatment with cytotoxic agents","volume":"210","author":"Santos","year":"1966","journal-title":"Nature."},{"key":"B36","doi-asserted-by":"publisher","first-page":"580","DOI":"10.1097\/00007890-198406000-00011","article-title":"Drug-induced tolerance to allografts in mice. I. Difference between tumor and skin grafts","volume":"37","author":"Shin","year":"1984","journal-title":"Transplantation."},{"key":"B37","doi-asserted-by":"publisher","first-page":"147","DOI":"10.1016\/S0171-2985(85)80029-2","article-title":"Drug-induced tolerance to allografts in mice II. Tolerance to tumor allografts of large doses associated with rejection of skin allografts and tumor allografts of small doses","volume":"169","author":"Mayumi","year":"1985","journal-title":"Immunobiology."},{"key":"B38","doi-asserted-by":"publisher","first-page":"209","DOI":"10.1097\/00007890-198502000-00019","article-title":"Drug-induced tolerance to allografts in mice. IV. Mechanisms and kinetics of cyclophosphamide-induced tolerance","volume":"39","author":"Mayumi","year":"1985","journal-title":"Transplantation."},{"key":"B39","doi-asserted-by":"publisher","first-page":"188","DOI":"10.1097\/00007890-198508000-00016","article-title":"Drug-induced tolerance to allografts in mice. VI. Tolerance induction in H-2-haplotype-identical strain combinations in mice","volume":"40","author":"Mayumi","year":"1985","journal-title":"Transplantation."},{"key":"B40","first-page":"2975","article-title":"Drug-induced tolerance to allografts in mice. XIII. Tolerance to the H-Y antigen","volume":"19","author":"Mayumi","year":"1987","journal-title":"Transplant Proc."},{"key":"B41","doi-asserted-by":"publisher","first-page":"335","DOI":"10.1097\/00007890-198503000-00032","article-title":"Drug-induced tolerance to allografts in mice. V. Prolongation of skin graft survival in tolerant mice with combined immunosuppressive treatments","volume":"39","author":"Mayumi","year":"1985","journal-title":"Transplantation."},{"key":"B42","doi-asserted-by":"crossref","first-page":"438","DOI":"10.1097\/00007890-198508000-00016","article-title":"Drug-induced tolerance to allografts in mice. VIII. Effects of thymectomy and\/or splenectomy on tolerance induction in an H-2-haplotype-identical strain combination","volume":"40","author":"Mayumi","year":"1985","journal-title":"Transplantation."},{"key":"B43","first-page":"363","article-title":"Drug-induced tolerance to allografts in mice. VII. Optimal protocol and mechanism of cyclophosphamide-induced tolerance in an H-2 haplotype-identical strain combination","volume":"18","author":"Mayumi","year":"1986","journal-title":"Transplant Proc."},{"key":"B44","doi-asserted-by":"publisher","first-page":"287","DOI":"10.1016\/S0171-2985(89)80053-1","article-title":"The necessity of both allogeneic antigens and stem cells for cyclophosphamide-induced skin allograft tolerance in mice","volume":"178","author":"Mayumi","year":"1989","journal-title":"Immunobiology."},{"key":"B45","doi-asserted-by":"publisher","first-page":"286","DOI":"10.1097\/00007890-198708000-00021","article-title":"Drug-induced tolerance to allografts in mice. XII. The relationships between tolerance, chimerism, and graft-versus-host disease","volume":"44","author":"Mayumi","year":"1987","journal-title":"Transplantation."},{"key":"B46","doi-asserted-by":"publisher","first-page":"451","DOI":"10.1097\/00007890-198809000-00024","article-title":"Dependency of cyclophosphamide-induced skin allograft tolerance on age of adult recipient mice","volume":"46","author":"Mayumi","year":"1988","journal-title":"Transplantation."},{"key":"B47","doi-asserted-by":"publisher","first-page":"213","DOI":"10.1084\/jem.169.1.213","article-title":"Long-lasting skin allograft tolerance in adult mice induced across fully allogeneic (multimajor H-2 plus multiminor histocompatibility) antigen barriers by a tolerance-inducing method using cyclophosphamide","volume":"169","author":"Mayumi","year":"1989","journal-title":"J Exp Med."},{"key":"B48","doi-asserted-by":"publisher","first-page":"86","DOI":"10.1016\/S0171-2985(89)80009-9","article-title":"Induction of tolerance across major barriers using a two-step method with genetic analysis of tolerance induction","volume":"179","author":"Mayumi","year":"1989","journal-title":"Immunobiology."},{"key":"B49","doi-asserted-by":"crossref","first-page":"1303","DOI":"10.4049\/jimmunol.145.5.1303","article-title":"Sequential mechanisms of cyclophosphamide-induced skin allograft tolerance including the intrathymic clonal deletion followed by late breakdown of the clonal deletion","volume":"145","author":"Eto","year":"1990","journal-title":"J Immunol."},{"key":"B50","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1084\/jem.171.1.97","article-title":"Intrathymic clonal deletion of V beta 6+ T cells in cyclophosphamide-induced tolerance to H-2-compatible, Mls-disparate antigens","volume":"171","author":"Eto","year":"1990","journal-title":"J Exp Med."},{"key":"B51","doi-asserted-by":"publisher","first-page":"A.1F.1","DOI":"10.1002\/0471142735.ima01fs17","article-title":"Mouse endogenous superantigens: Ms and Mls-like determinants encoded by mouse retroviruses","volume":"17","author":"Hodes","year":"2001","journal-title":"Curr Protoc Immunol."},{"key":"B52","doi-asserted-by":"publisher","first-page":"2005","DOI":"10.1002\/eji.1830200919","article-title":"The requirement of intrathymic mixed chimerism and clonal deletion for a long-lasting skin allograft tolerance in cyclophosphamide-induced tolerance","volume":"20","author":"Eto","year":"1990","journal-title":"Eur J Immunol."},{"key":"B53","doi-asserted-by":"crossref","first-page":"1402","DOI":"10.4049\/jimmunol.146.5.1402","article-title":"Specific destruction of host-reactive mature T cells of donor origin prevents graft-versus-host disease in cyclophosphamide-induced tolerant mice","volume":"146","author":"Eto","year":"1991","journal-title":"J Immunol."},{"key":"B54","doi-asserted-by":"crossref","first-page":"463","DOI":"10.4049\/jimmunol.144.2.463","article-title":"Importance of suppressor T cells in cyclophosphamide-induced tolerance to the non-H-2-encoded alloantigens. Is mixed chimerism really required in maintaining a skin allograft tolerance?","volume":"144","author":"Tomita","year":"1990","journal-title":"J Immunol."},{"key":"B55","doi-asserted-by":"crossref","first-page":"5284","DOI":"10.4049\/jimmunol.157.12.5284","article-title":"Regulatory T cells in maintenance and reversal of peripheral tolerance in vivo","volume":"157","author":"Kong","year":"1996","journal-title":"J Immunol."},{"key":"B56","doi-asserted-by":"crossref","first-page":"4026","DOI":"10.4049\/jimmunol.145.12.4026","article-title":"Evidence for involvement of clonal anergy in MHC class I and class II disparate skin allograft tolerance after the termination of intrathymic clonal deletion","volume":"145","author":"Tomita","year":"1990","journal-title":"J Immunol."},{"key":"B57","doi-asserted-by":"crossref","first-page":"2820","DOI":"10.4049\/jimmunol.157.7.2820","article-title":"Durable mixed allogeneic chimerism and tolerance by a non-lethal radiation-based cytoreductive approach","volume":"157","author":"Colson","year":"1996","journal-title":"J Immunol."},{"key":"B58","doi-asserted-by":"crossref","first-page":"4179","DOI":"10.4049\/jimmunol.155.9.4179","article-title":"A non-lethal conditioning approach to achieve durable multilineage mixed chimerism and tolerance across major, minor, and hematopoietic histocompatibility barriers","volume":"155","author":"Colson","year":"1995","journal-title":"J Immunol."},{"key":"B59","doi-asserted-by":"publisher","first-page":"3456","DOI":"10.1182\/blood.V98.12.3456","article-title":"Durable engraftment of major histocompatibility complex-incompatible cells after non-myeloablative conditioning with fludarabine, low-dose total body irradiation, and posttransplantation cyclophosphamide","volume":"98","author":"Luznik","year":"2001","journal-title":"Blood."},{"key":"B60","doi-asserted-by":"publisher","first-page":"131","DOI":"10.1053\/bbmt.2002.v8.pm11939602","article-title":"Posttransplantation cyclophosphamide facilitates engraftment of major histocompatibility complex-identical allogeneic marrow in mice conditioned with low-dose total body irradiation","volume":"8","author":"Luznik","year":"2002","journal-title":"Biol Blood Marrow Transplant."},{"key":"B61","doi-asserted-by":"publisher","first-page":"124ra28","DOI":"10.1126\/scitranslmed.3003509","article-title":"Chimerism and tolerance without GVHD or engraftment syndrome in HLA-mismatched combined kidney and hematopoietic stem cell transplantation","volume":"4","author":"Leventhal","year":"2012","journal-title":"Sci Transl Med."},{"key":"B62","doi-asserted-by":"publisher","first-page":"169","DOI":"10.1097\/TP.0b013e3182782fc1","article-title":"Tolerance induction in HLA disparate living donor kidney transplantation by donor stem cell infusion: durable chimerism predicts outcome","volume":"95","author":"Leventhal","year":"2013","journal-title":"Transplantation."},{"key":"B63","doi-asserted-by":"publisher","first-page":"274","DOI":"10.1016\/S0171-2985(87)80003-7","article-title":"Drug-induced tolerance to allografts in mice. X. Augmentation of split tolerance in murine combinations disparate at both H-2 and non-H-2 antigens by the use of spleen cells from donors preimmunized with recipient antigens","volume":"174","author":"Mayumi","year":"1987","journal-title":"Immunobiology."},{"key":"B64","doi-asserted-by":"publisher","first-page":"197","DOI":"10.1016\/j.bbmt.2014.10.008","article-title":"High fever occurring 4 to 5 days post-transplant of haploidentical bone marrow or peripheral blood stem cells after reduced-intensity conditioning associated with the use of post-transplant cyclophosphamide as prophylaxis for graft-versus-host disease","volume":"21","author":"O'Donnell","year":"2015","journal-title":"Biol Blood Marrow Transplant."},{"key":"B65","doi-asserted-by":"publisher","first-page":"1859","DOI":"10.1016\/j.bbmt.2012.06.019","article-title":"Haploidentical transplantation using T cell replete peripheral blood stem cells and myeloablative conditioning in patients with high-risk hematologic malignancies who lack conventional donors is well-tolerated and produces excellent relapse-free survival: results of a prospective phase II trial","volume":"18","author":"Solomon","year":"2012","journal-title":"Biol Blood Marrow Transplant."},{"key":"B66","doi-asserted-by":"publisher","first-page":"612","DOI":"10.1016\/S0140-6736(83)91793-2","article-title":"Mismatched family donors for bone-marrow transplantation as treatment for acute leukaemia","volume":"1","author":"Powles","year":"1983","journal-title":"Lancet."},{"key":"B67","doi-asserted-by":"publisher","first-page":"417","DOI":"10.1097\/00007890-198610000-00018","article-title":"Drug-induced tolerance to allografts in mice. IX. Establishment of complete chimerism by allogeneic spleen cell transplantation from donors made tolerant to H-2-identical recipients","volume":"42","author":"Mayumi","year":"1986","journal-title":"Transplantation."},{"key":"B68","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1007\/s12026-009-8139-0","article-title":"High-dose, post-transplantation cyclophosphamide to promote graft-host tolerance after allogeneic hematopoietic stem cell transplantation","volume":"47","author":"Luznik","year":"2010","journal-title":"Immunol Res."},{"key":"B69","doi-asserted-by":"publisher","first-page":"343","DOI":"10.1016\/j.bbmt.2017.10.023","article-title":"Grade II acute graft-versus-host disease and higher nucleated cell graft dose improve progression-free survival after HLA-haploidentical transplant with post-transplant cyclophosphamide","volume":"24","author":"McCurdy","year":"2018","journal-title":"Biol Blood Marrow Transplant."},{"key":"B70","doi-asserted-by":"publisher","first-page":"1502","DOI":"10.1182\/blood-2015-10-672071","article-title":"Posttransplantation cyclophosphamide for prevention of graft-versus-host disease after HLA-matched mobilized blood cell transplantation","volume":"127","author":"Mielcarek","year":"2016","journal-title":"Blood."},{"key":"B71","doi-asserted-by":"publisher","first-page":"3152","DOI":"10.1200\/JCO.2014.60.4777","article-title":"Outcomes of non-myeloablative HLA-haploidentical blood or marrow transplantation with high-dose post-transplantation cyclophosphamide in older adults","volume":"33","author":"Kasamon","year":"2015","journal-title":"J Clin Oncol."},{"key":"B72","doi-asserted-by":"publisher","first-page":"921","DOI":"10.1016\/j.exphem.2015.07.006","article-title":"HLA haploidentical peripheral blood stem cell transplantation using reduced dose of posttransplantation cyclophosphamide for poor-prognosis or refractory leukemia and myelodysplastic syndrome","volume":"43","author":"Nakamae","year":"2015","journal-title":"Exp Hematol."},{"key":"B73","doi-asserted-by":"publisher","first-page":"e1356152","DOI":"10.1080\/2162402X.2017.1356152","article-title":"Low-dose post-transplant cyclophosphamide can mitigate GVHD and enhance the G-CSF\/ATG induced GVHD protective activity and improve haploidentical transplant outcomes","volume":"6","author":"Wang","year":"2017","journal-title":"Oncoimmunology."},{"key":"B74","doi-asserted-by":"crossref","first-page":"2668","DOI":"10.4049\/jimmunol.149.8.2668","article-title":"Interference with cyclophosphamide-induced skin allograft tolerance by cyclosporin A","volume":"149","author":"Nomoto","year":"1992","journal-title":"J Immunol."},{"key":"B75","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1016\/j.bbmt.2012.08.014","article-title":"Unmanipulated haploidentical bone marrow transplantation and posttransplantation cyclophosphamide for hematologic malignancies after myeloablative conditioning","volume":"19","author":"Raiola","year":"2013","journal-title":"Biol Blood Marrow Transplant."},{"key":"B76","doi-asserted-by":"publisher","first-page":"1243","DOI":"10.1016\/j.bbmt.2018.01.031","article-title":"A modified post-transplant cyclophosphamide regimen, for unmanipulated haploidentical marrow transplantation, in acute myeloid leukemia: a multicenter study","volume":"24","author":"Chiusolo","year":"2018","journal-title":"Biol Blood Marrow Transplant."},{"key":"B77","doi-asserted-by":"publisher","first-page":"2855","DOI":"10.1182\/blood-2014-11-608406","article-title":"Role of naive-derived T memory stem cells in T-cell reconstitution following allogeneic transplantation","volume":"125","author":"Roberto","year":"2015","journal-title":"Blood."},{"key":"B78","doi-asserted-by":"publisher","first-page":"2865","DOI":"10.1182\/blood-2014-11-608539","article-title":"Generation of human memory stem T cells after haploidentical T-replete hematopoietic stem cell transplantation","volume":"125","author":"Cieri","year":"2015","journal-title":"Blood."},{"key":"B79","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbmt.2019.09.030","article-title":"Optimized timing of post-transplantation cyclophosphamide in MHC-haploidentical murine hematopoietic cell transplantation","author":"Wachsmuth","year":"2019","journal-title":"Biol Blood Marrow Transpl."},{"key":"B80","doi-asserted-by":"publisher","first-page":"e86252","DOI":"10.1172\/jci.insight.86252","article-title":"Origin and evolution of the T cell repertoire after posttransplantation cyclophosphamide","volume":"1","author":"Kanakry","year":"2016","journal-title":"JCI Insight."},{"key":"B81","doi-asserted-by":"publisher","first-page":"2649","DOI":"10.1182\/blood-2006-08-044529","article-title":"In vivo dynamics of regulatory T-cell trafficking and survival predict effective strategies to control graft-versus-host disease following allogeneic transplantation","volume":"109","author":"Nguyen","year":"2007","journal-title":"Blood."},{"key":"B82","doi-asserted-by":"publisher","first-page":"3921","DOI":"10.1182\/blood-2010-10-311894","article-title":"Tregs prevent GVHD and promote immune reconstitution in HLA-haploidentical transplantation","volume":"117","author":"Di Ianni","year":"2011","journal-title":"Blood."},{"key":"B83","doi-asserted-by":"publisher","first-page":"477","DOI":"10.7326\/0003-4819-135-7-200110020-00006","article-title":"Durable treatment-free remission after high-dose cyclophosphamide therapy for previously untreated severe aplastic anemia","volume":"135","author":"Brodsky","year":"2001","journal-title":"Ann Intern Med."},{"key":"B84","doi-asserted-by":"publisher","first-page":"1506","DOI":"10.1016\/j.bbmt.2015.04.025","article-title":"Post-transplantation cyclophosphamide and sirolimus after haploidentical hematopoietic stem cell transplantation using a treosulfan-based myeloablative conditioning and peripheral blood stem cells","volume":"21","author":"Cieri","year":"2015","journal-title":"Biol Blood Marrow Transplant."},{"key":"B85","doi-asserted-by":"publisher","first-page":"4955","DOI":"10.1182\/blood-2013-03-489757","article-title":"A distinct evolution of the T-cell repertoire categorizes treatment refractory gastrointestinal acute graft-versus-host disease","volume":"121","author":"Meyer","year":"2013","journal-title":"Blood."},{"key":"B86","doi-asserted-by":"publisher","first-page":"247","DOI":"10.1182\/blood-2017-05-780668","article-title":"NK cell recovery after haploidentical HSCT with posttransplant cyclophosphamide: dynamics and clinical implications","volume":"131","author":"Russo","year":"2018","journal-title":"Blood."},{"key":"B87","doi-asserted-by":"publisher","first-page":"40","DOI":"10.1016\/j.trim.2013.11.003","article-title":"Post-transplant cyclophosphamide and bortezomib inhibit dendritic cell maturation and function and alter their IkappaB and NFkappaB","volume":"30","author":"Al-Homsi","year":"2014","journal-title":"Transpl Immunol."},{"key":"B88","doi-asserted-by":"publisher","first-page":"e140","DOI":"10.1097\/TP.0000000000001480","article-title":"Induction of major histocompatibility complex-mismatched mouse lung allograft acceptance with combined donor bone marrow: lung transplant using a 12-hour nonmyeloablative conditioning regimen","volume":"100","author":"Dodd","year":"2016","journal-title":"Transplantation."},{"key":"B89","doi-asserted-by":"publisher","first-page":"288","DOI":"10.1097\/TP.0000000000000605","article-title":"Immune reconstitution\/immunocompetence in recipients of kidney plus hematopoietic stem\/facilitating cell transplants","volume":"99","author":"Leventhal","year":"2015","journal-title":"Transplantation."},{"key":"B90","doi-asserted-by":"publisher","first-page":"211","DOI":"10.1182\/blood.2019000775","article-title":"Haploidentical hematopoietic cell and kidney transplantation for hematological malignancies and end-stage renal failure","volume":"134","author":"Chen","year":"2019","journal-title":"Blood."},{"key":"B91","doi-asserted-by":"publisher","first-page":"272ra10","DOI":"10.1126\/scitranslmed.3010760","article-title":"Tracking donor-reactive T cells: evidence for clonal deletion in tolerant kidney transplant patients","volume":"7","author":"Morris","year":"2015","journal-title":"Sci Transl Med."},{"key":"B92","doi-asserted-by":"publisher","first-page":"3024","DOI":"10.1182\/blood-2015-01-623991","article-title":"Risk-stratified outcomes of non-myeloablative HLA-haploidentical BMT with high-dose posttransplantation cyclophosphamide","volume":"125","author":"McCurdy","year":"2015","journal-title":"Blood."},{"key":"B93","doi-asserted-by":"publisher","first-page":"1108","DOI":"10.1016\/j.bbmt.2018.04.004","article-title":"Teaching a young dog new tricks: modifications to the post-transplantation cyclophosphamide haploidentical transplantation platform","volume":"24","author":"Kanakry","year":"2018","journal-title":"Biol Blood Marrow Transplant."}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/article\/10.3389\/fimmu.2019.02668\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,23]],"date-time":"2023-09-23T13:19:53Z","timestamp":1695475193000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/article\/10.3389\/fimmu.2019.02668\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,11,29]]},"references-count":93,"alternative-id":["10.3389\/fimmu.2019.02668"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2019.02668","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,11,29]]},"article-number":"2668"}}